EUVIMEDEUVIMED entdecken
Crossref

INTRALESIONAL MEGLUMINE ANTIMONIATE VERSUS PLASMA RICH PLATELETS: COMPARISON OF EFFICACY IN CUTANEOUS LEISHMANIASIS

Chinese Journal of Cancer Prevention and Treatment · 20.07.2026 · 33 (7) · 14-17

DOI: 10.61336/cjpt/26-7-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chinese Journal of Cancer Prevention and Treatment, online erschienen am 20.07.2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cutaneous Leishmaniasis (CL), associated with considerable morbidity, is still a major health problem in the world, especially in developing countries. The intralesional infiltration of meglumine antimoniate (MA) is considered among the standard therapies for the New World Leishmaniasis. Platelet-rich plasma (PRP) is a promising therapy in dermatology and aesthetic medicine. PRP is an autologous serum containing high concentrations of platelets and growth factors. It has been used in dermatology for the treatment of various ulcers with variable successful results. This study compares the efficacy of Intralesional PRP with Intralesional meglumine antimoniate in the treatment of CL. OBJECTIVE: To compare the efficacy of intralesional Meglumine Antimoniate and intralesional PRP in the treatment of CL. STUDY DESIGN: Cross-sectional; Prospective DURATION OF STUDY: 17-01-2020 to 16-07-2020 DATA COLLECTION PROCEDURE: A total of 60 participants with Cutaneous Leishmaniasis were equally divided among two groups randomly, one was treated with Intralesional Meglumine Antimoniate (group 1) and the other with Intralesional Platelet-rich Plasma (group 2). Group 1 patients were given intralesional meglumine antimoniate, Group 2 patients received intralesional PRP. Lesions were reassessed after 4 weeks. RESULT: Higher efficacy in the Intralesional Platelet-rich Plasma group was found in almost all the sub-groups of patients by demographic and disease characteristics such as age, gender, education status, socioeconomic status, duration of disease, site of lesion, number of lesions, size of lesion, and diagnosis. The efficacy rate was found to be significantly higher in Intralesional Platelet-rich Plasma (group 2) as compared to Intralesional Meglumine Antimoniate (group 1), with an efficacy rate of 86.7% (26) vs. 50% (15); p=0.002, respectively. CONCLUSION: Although this study showed a significantly better outcome in terms of treatment by PRP, but exact mechanism that leads to the resolution of parasitic infection needs to be studied at the molecular level as well

Zitieren

APA

(2026). INTRALESIONAL MEGLUMINE ANTIMONIATE VERSUS PLASMA RICH PLATELETS: COMPARISON OF EFFICACY IN CUTANEOUS LEISHMANIASIS. Chinese Journal of Cancer Prevention and Treatment, 33(7), 14-17. https://doi.org/10.61336/cjpt/26-7-3

Vancouver

INTRALESIONAL MEGLUMINE ANTIMONIATE VERSUS PLASMA RICH PLATELETS: COMPARISON OF EFFICACY IN CUTANEOUS LEISHMANIASIS. Chinese Journal of Cancer Prevention and Treatment. 2026;33(7):14-17. doi:10.61336/cjpt/26-7-3

BibTeX
@article{euvimed2026,
  title = {INTRALESIONAL MEGLUMINE ANTIMONIATE VERSUS PLASMA RICH PLATELETS: COMPARISON OF EFFICACY IN CUTANEOUS LEISHMANIASIS},
  journal = {Chinese Journal of Cancer Prevention and Treatment},
  year = {2026},
  volume = {33},
  number = {7},
  pages = {14--17},
  doi = {10.61336/cjpt/26-7-3}
}
Kostenlos starten →